HRS 7058
Alternative Names: HRS-7058Latest Information Update: 02 Jul 2024
At a glance
- Originator Shandong Suncadia Medicine
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 02 Jul 2024 Phase-I clinical trials in Solid tumours (In adults, In the elderly, Late-stage disease, Metastatic disease, Monotherapy) (PO), prior to July 2024 (NCT06383871) (Shandong Suncadia Medicine pipeline, July 2024)
- 30 Apr 2024 Shandong Suncadia Medicine plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Monotherapy) in unknown location (PO, Tablet, Capsule) (NCT06383871)
- 25 Apr 2024 Preclinical trials in Solid tumours in China (PO) prior to April 2024